CAB7-3

CAB7-3 (0.001-1 μM, 6 days) shows an antiviral activity in HepAD38 cells with EC₅₀ = 1 nM, CC₅₀ = 26.54 μM, SI = 26540; in HepDES19 cells with EC₅₀ = 7 nM, CC₅₀ = 32 μM, SI = 481; in HBV-infected HLCZ01 cells with EC₅₀ = 2 nM, CC₅₀ = 30.73 μM, SI = 15365^[1].
CAB7-3 (0.0003-1 μM, 6 days) blocks new cccDNA formation while leaving HBsAg secretion from pre-existing cccDNA unaffected in HepAD38 and HLCZ01 cells^[1].
CAB7-3 (0.006-4 μM, 3 days ) induces HBV Cp degradation and disrupts capsid assembly in HepG2 cells^[1].
CAB7-3 (1 mg in 1 mL DMSO and 0.5 mg in 0.5 mL DMSO) shows water solubility (257.42 μg/mL, pH 2.0; 2.57 μg/mL, pH 7.0; 4.14 μg/mL, pH 7.4)^[1].
CAB7-3 (1 μM, 0-60 min) shows T^1/2 = 169 min, CL^int(mic) = 8.2 μL/min/mg, CL^int(liver) = 7.4 mL/min/kg and Remaining (T = 60 min) = 78.0% in human microsomes CAB7-3 (10 μM, ) not induce CYP3A4 in primary human hepatocytes (PHHs) ^[1].
CAB7-3 (0.3-100 μM) exhibits significantly low inhibitory rates on the hERG channel in HEK293 cells with hERG inhibition = 3.52, 14.59, 31.84, 61.05, 83.05, 94.76 % at concentration of 0.3, 1, 3, 10, 30 and 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.